January 13, 2020 Portfolio News from ARCH Venture Partners | Share A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
October 10, 2019 Portfolio News from ARCH Venture Partners | Share Vir Biotechnology Announces Pricing of Initial Public Offering
September 19, 2019 Portfolio News from ARCH Venture Partners | Share A Biotech Startup Hopes to Disarm Cancer by Targeting a Genetic Bandolier
June 28, 2019 Portfolio News from ARCH Venture Partners | Share Karuna Makes Nasdaq Debut with $89M IPO
June 26, 2019 Portfolio News from ARCH Venture Partners | Share After Raising $158M, This Upstart’s Founders Have Star Backers and Plans to Break New Ground in Gene Therapy
June 14, 2019 Portfolio News from ARCH Venture Partners | Share BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health
May 23, 2019 Portfolio News from ARCH Venture Partners | Share Locana Launches with $55M for RNA-Targeting Gene Therapies
March 18, 2019 Portfolio News from ARCH Venture Partners | Share Karuna Announces $68 Million Series B Financing
March 12, 2019 ARCH News from ARCH Venture Partners | Share ARCH Receives NVCA Firm Of The Year Award
March 6, 2019 Portfolio News from ARCH Venture Partners | Share Gene editing startup Beam Therapeutics raises $135M Series B round
March 5, 2019 Portfolio News from ARCH Venture Partners | Share Erasca™- AI Oncology Startup Announces Series A Extension
March 1, 2019 Portfolio News from ARCH Venture Partners | Share Maze Therapeutics Launches to Focus on Translating Genetic Insights into New Medicines
